GSK 3326595

Drug Profile

GSK 3326595

Alternative Names: 3326595; EPZ-015938; GSK-3326595

Latest Information Update: 17 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Epizyme
  • Developer GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action Protein-arginine N-methyltransferase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Sep 2016 GSK 3326595 licensed to GlaxoSmithKline worldwide
  • 15 Sep 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma in USA (PO) (NCT02783300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top